Form 4: Phibro Animal Health CEO Sells PAHC Stock via 10b5-1 Plan

Phibro Animal Health Corp's President and CEO, Jack Bendheim, reported sales of Class A Common Stock totaling 21,180 shares through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC, a 10% owner, reported sales of Class A Common Stock.
• A total of 21,180 shares of Class A Common Stock were sold by BFI Co., LLC between March 24, 2026, and March 26, 2026.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on December 11, 2025.
• The shares were sold at weighted average prices ranging from $52.8772 to $57.1702 per share.
• Following these transactions, BFI Co., LLC indirectly beneficially owns 52,200 shares, and Jack Bendheim directly beneficially owns 16,840 shares.
• Jack Bendheim exercises voting and dispositive power over BFI Co., LLC's holdings and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be a negative signal, the execution under a pre-arranged 10b5-1 plan mitigates concerns that the sales are based on new, adverse non-public information.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating the transactions were scheduled in advance and not a reaction to recent non-public information.

Negatives

• Significant insider selling by a key executive (President and CEO) and a 10% owner could be perceived negatively by investors, potentially signaling a lack of confidence or a belief that the stock is fully valued.

Risks

• Investor perception of insider selling may lead to negative sentiment or downward pressure on the stock price.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider selling, even when pre-planned, is a common occurrence across industries. The animal health sector, where Phibro operates, is generally stable, but such sales are typically viewed in the context of individual executive financial planning rather than broader industry trends unless accompanied by other significant company news.

Related Party Transactions

• Sales were made by BFI Co., LLC, over which Jack Bendheim, a reporting person, director, and officer of the Issuer, exercises voting and dispositive power. Mr. Bendheim may be deemed to have shared voting and investment power over the securities held by BFI and disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may view the insider selling by the CEO and a 10% owner with caution, potentially leading to questions about management's long-term confidence in the company's valuation, despite the pre-planned nature of the sales.

Key Dates

Recommendation

While the sales by the CEO and 10% owner are notable, they were conducted under a pre-arranged 10b5-1 plan, which suggests the transactions are for personal financial planning rather than a reaction to new company-specific negative developments. Without additional context from financial reports or strategic updates, a 'hold' recommendation is appropriate, advising investors to monitor future company performance and insider activity.

Keywords

PAHC, Phibro Animal Health, insider trading, Form 4, stock sale, Jack Bendheim, 10b5-1 plan, CEO stock sale